×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Gastritis Treatment Market Trends

ID: MRFR/Pharma/4769-HCR
90 Pages
Rahul Gotadki
October 2025

Gastritis Treatment Market Research Report Information By Diagnosis (Blood Test and Endoscopy), Treatment (Acid Blocking Medicines and Antibiotics), Drug Distribution Channel (Retail Pharmacy), and End-User (Hospitals and Clinics) - Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Gastritis Treatment Market Infographic
Purchase Options

Market Trends

Key Emerging Trends in the Gastritis Treatment Market

The current situation for treating gastritis has witnessed major shifts in trends over recent years, as a result of new therapies, rising incidence of gastritis-related conditions and development in personalized medicine. Gastritis - inflammation of the lining of the stomach – is moving towards more targeted approaches to therapy, which are also more effective. One important trend among them is increasing awareness and diagnosis of gastritis due to better understanding of factors that cause it like Helicobacter pylori infection, chronic use of certain drugs and lifestyle choices. Such a heightened attention has resulted in earlier detection and intervention impacting positively on the market for treatments related to gastritis.

Therapeutic advancements play an important role in shaping the treatment landscape for gastritis. This market has seen the introduction of new medications such as proton pump inhibitors (PPIs) and H2 receptor blockers which effectively reduce production of acid in the stomach. Besides, there have been advances in antibiotic formulations with increased effectiveness against H. pylori, thus improving therapeutic interventions for patients with bacterial related gastritis. These efforts not only alleviate symptoms but also address etiological causes of gastritis resulting into more inclusive or focused approaches towards its management.

There is another significant tendency that can be identified within the field – a growing interest towards precision therapeutics and personalized medicine applied to this particular disease. As knowledge about different types of gastritis variability increases, it implies that treatment programs should be tailored individually based on personal peculiarities such as specific causes behind their occurrence, severity levels or reaction to medications demonstrated by patients themselves. Therefore, this personalized method seeks better outcomes through suitable treatment plans where side effects can be minimized leading to enhanced patient-centred approach in managing gastric problems.

In addition to this, researchers have observed increased R&D activities by pharmaceutical companies into finding novel therapeutic solutions for people with gastric disorders. From investigating new drug classes up to exploring alternative forms of treatments available today; they are working towards methods that promise improved safety and efficacy. This research driven trend is expected to increase the number of available therapies, which provides more options to healthcare professionals when dealing with patients having various types of gastritis.

The practice of integrating complementary and alternative medicine (CAM) approaches into gastritis treatment can be mentioned as one such tendency. Non-pharmacological interventions like changing diets, using herbal products or even acupuncture is being embraced by patients alongside traditional medical practices. It shows an increased interest in holistic and integrative ways of managing gastritis as both patients and medical practitioners acknowledge possible synergism between conventional medicines and their complementary alternatives.

today’s gastritis treatment market is incomplete without digital health solutions and telemedicine. These technologies support remote patient monitoring, improve communication between patients and doctors as well as adherence to the treatment process. Particularly throughout Covid-19 pandemic, there has been a lot of reliance on telemedicine for people with gastritis to access healthcare services.

Market trends also show a growing focus on gastrointestinal health generally as wells overall wellness issues. There are now greater numbers of awareness campaigns, educational initiatives and changes in lifestyle stressing the significance in preventing or treating diseases like gastric ulcers of having a balanced diet; stress management techniques; healthy decisions. Thus, this holistic approach is based on the assumption that lifestyle factors can significantly influence course or severity levels associated with gastritis cases.

In market, regulatory considerations and streamlining of approval processes for gastritis treatments are important trend. It is important to note that regulatory bodies collaborate with stakeholders in the industry to ensure thorough assessment of new therapies on their safety and effectiveness for patients while at the same time making them available as quickly as possible. Through this joint approach, a more effective and flexible regulatory environment has been developed for treating gastritis.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

FAQs

What is the projected market valuation for the Gastritis Treatment Market in 2035?

The projected market valuation for the Gastritis Treatment Market in 2035 is expected to reach 0.561 USD Billion.

What was the market valuation for the Gastritis Treatment Market in 2024?

The overall market valuation for the Gastritis Treatment Market was 0.14 USD Billion in 2024.

What is the expected CAGR for the Gastritis Treatment Market from 2025 to 2035?

The expected CAGR for the Gastritis Treatment Market during the forecast period 2025 - 2035 is 13.45%.

Which companies are considered key players in the Gastritis Treatment Market?

Key players in the Gastritis Treatment Market include Pfizer, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Takeda Pharmaceutical, Sanofi, AbbVie, and Mylan.

What are the primary segments of the Gastritis Treatment Market?

The primary segments of the Gastritis Treatment Market include Diagnosis, Treatment Type, Drug Distribution Channel, and End-User.

Market Summary

As per MRFR analysis, the Gastritis Treatment Market Size was estimated at 0.14 USD Billion in 2024. The Gastritis Treatment industry is projected to grow from 0.1588 in 2025 to 0.561 by 2035, exhibiting a compound annual growth rate (CAGR) of 13.45 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Gastritis Treatment Market is experiencing a dynamic shift towards personalized and preventive care solutions.

  • The demand for personalized medicine is rising, reflecting a broader trend in healthcare towards tailored treatment options.
  • Digital health solutions are increasingly integrated into gastritis management, enhancing patient engagement and monitoring.
  • Preventive care and lifestyle modifications are gaining traction, indicating a shift in focus from reactive to proactive healthcare.
  • The increasing prevalence of gastritis and advancements in pharmaceutical research are driving market growth, particularly in North America and Asia-Pacific.

Market Size & Forecast

2024 Market Size 0.14 (USD Billion)
2035 Market Size 0.561 (USD Billion)
CAGR (2025 - 2035) 13.45%
Largest Regional Market Share in 2024 Americas

Major Players

<p>Pfizer (US), Novartis (CH), Bristol-Myers Squibb (US), GlaxoSmithKline (GB), AstraZeneca (GB), Takeda Pharmaceutical (JP), Sanofi (FR), AbbVie (US), Mylan (US)</p>

Market Trends

The Gastritis Treatment Market is currently experiencing a notable evolution, driven by a combination of increasing awareness regarding gastrointestinal health and advancements in therapeutic options. As individuals become more informed about the implications of gastritis, there is a growing demand for effective treatment modalities. This market encompasses a range of therapies, including medications, lifestyle modifications, and dietary interventions, which collectively aim to alleviate symptoms and address underlying causes. Furthermore, the integration of technology in healthcare is facilitating more personalized treatment approaches, enhancing patient outcomes and satisfaction. In addition to the rising awareness, the Gastritis Treatment Market is also influenced by ongoing research and development efforts aimed at discovering novel therapeutic agents. Pharmaceutical companies are increasingly investing in the development of innovative drugs that target specific pathways involved in gastritis. This trend suggests a potential shift towards more effective and tailored treatments, which may improve the quality of life for patients. Moreover, the collaboration between healthcare providers and researchers is likely to foster a more comprehensive understanding of gastritis, ultimately leading to better management strategies and improved patient care.

Rising Demand for Personalized Medicine

The Gastritis Treatment Market is witnessing a shift towards personalized medicine, where treatments are tailored to individual patient profiles. This trend is driven by advancements in genetic research and a deeper understanding of the disease mechanisms. As healthcare providers increasingly recognize the importance of individualized care, patients may benefit from therapies that are more effective and have fewer side effects.

Integration of Digital Health Solutions

The incorporation of digital health solutions is transforming the Gastritis Treatment Market. Telemedicine, mobile health applications, and online support groups are becoming more prevalent, allowing patients to access care and information conveniently. This trend not only enhances patient engagement but also facilitates better monitoring of treatment adherence and symptom management.

Focus on Preventive Care and Lifestyle Modifications

There is a growing emphasis on preventive care and lifestyle modifications within the Gastritis Treatment Market. Healthcare professionals are increasingly advocating for dietary changes, stress management, and other lifestyle interventions as integral components of treatment. This proactive approach aims to reduce the incidence of gastritis and improve overall gastrointestinal health.

Gastritis Treatment Market Market Drivers

Rising Healthcare Expenditure

The increase in healthcare expenditure across various regions is positively impacting the Gastritis Treatment Market. As governments and private sectors allocate more resources to healthcare, access to treatment options for gastritis is improving. This trend is particularly evident in developing nations, where investments in healthcare infrastructure are expanding. Enhanced access to medical services and treatments is likely to lead to a rise in gastritis diagnoses and subsequent treatment demands. Furthermore, the growing trend of health insurance coverage is facilitating patient access to necessary medications and therapies, thereby driving market growth. As healthcare spending continues to rise, the Gastritis Treatment Market is expected to benefit significantly.

Increasing Prevalence of Gastritis

The rising incidence of gastritis is a primary driver for the Gastritis Treatment Market. Factors such as unhealthy dietary habits, increased alcohol consumption, and the prevalence of Helicobacter pylori infections contribute to this trend. According to health statistics, gastritis affects millions worldwide, leading to a growing demand for effective treatment options. The market is projected to expand as more individuals seek medical attention for gastritis-related symptoms. This increasing prevalence not only highlights the need for innovative therapies but also emphasizes the importance of awareness and education regarding gastritis management. As healthcare providers focus on addressing this condition, the Gastritis Treatment Market is likely to witness significant growth in the coming years.

Advancements in Pharmaceutical Research

Innovations in pharmaceutical research are propelling the Gastritis Treatment Market forward. The development of new medications, including proton pump inhibitors and antibiotics targeting H. pylori, has transformed treatment protocols. Recent studies indicate that the market for gastritis medications is expected to grow at a compound annual growth rate of over 5% in the next few years. These advancements not only improve patient outcomes but also enhance the overall efficacy of gastritis management. Furthermore, ongoing research into novel therapeutic agents and combination therapies may provide additional options for patients, thereby expanding the market landscape. As the industry evolves, the introduction of new drugs is anticipated to play a crucial role in shaping treatment paradigms.

Integration of Telemedicine in Gastroenterology

The integration of telemedicine into gastroenterology practices is emerging as a key driver for the Gastritis Treatment Market. Telehealth services enable patients to consult healthcare professionals remotely, improving access to care for those suffering from gastritis. This trend is particularly beneficial for individuals in rural or underserved areas, where specialist access may be limited. The convenience of telemedicine encourages patients to seek timely treatment, which can lead to better management of gastritis symptoms. As telehealth continues to gain traction, the Gastritis Treatment Market is likely to see an increase in patient engagement and adherence to treatment plans, ultimately enhancing overall health outcomes.

Growing Awareness of Gastritis and Its Complications

Increased awareness regarding gastritis and its potential complications is driving the Gastritis Treatment Market. Educational campaigns by healthcare organizations have led to a better understanding of gastritis symptoms and the importance of early diagnosis. This heightened awareness encourages individuals to seek medical advice sooner, resulting in a higher demand for treatment options. Moreover, complications associated with untreated gastritis, such as peptic ulcers and gastric cancer, further underscore the necessity for effective management strategies. As patients become more informed about their health, the Gastritis Treatment Market is likely to experience a surge in demand for both pharmacological and non-pharmacological interventions.

Market Segment Insights

By Diagnosis: Blood Test (Largest) vs. Endoscopy (Fastest-Growing)

<p>In the Gastritis Treatment Market, the diagnosis segment is primarily dominated by blood tests, which have established a reliable presence due to their non-invasive nature and ability to offer quick results. Endoscopy, however, is emerging as a vital diagnostic tool, particularly for cases where more direct visualization of the stomach lining is required. Although currently smaller in market share, its usage is growing rapidly as technological advancements improve effectiveness and reduce associated risks, making it a preferred choice in certain clinical scenarios. The growth trends in the diagnosis segment indicate a rising preference for advanced diagnostic procedures that provide comprehensive insights into gastric conditions. Factors such as increasing awareness regarding gastritis among patients and healthcare providers, alongside the growing prevalence of gastrointestinal disorders, are driving demand for more sophisticated diagnostic tools. Additionally, innovations in endoscopy technologies, which enhance precision and safety, contribute significantly to the segment's upward trajectory, positioning endoscopy as a crucial player in the gastritis treatment landscape.</p>

<p>Blood Test (Dominant) vs. Endoscopy (Emerging)</p>

<p>Blood tests remain the dominant method for diagnosing gastritis, favored for their simplicity and effectiveness in assessing general health and potential inflammation markers. They are routinely used in various healthcare settings, making them accessible for many patients. In contrast, endoscopy is considered an emerging choice for diagnosis, allowing direct examination of the stomach lining and potential biopsy of suspicious areas. This method is particularly valuable in complex or chronic cases, providing crucial insights that blood tests cannot. The combination of these methods enriches the diagnostic arsenal for healthcare professionals, catering to a diverse range of patient needs.</p>

By Treatment type: Acid-blocking medicines (Largest) vs. Antibiotics (Fastest-Growing)

<p>In the Gastritis Treatment Market, acid-blocking medicines command the largest share due to their effectiveness in reducing gastric acid production and alleviating symptoms. This category includes proton pump inhibitors and H2-receptor antagonists that have gained widespread acceptance among healthcare providers. On the other hand, antibiotics are emerging as a fast-growing segment, especially with the rising prevalence of Helicobacter pylori infections, which are a significant contributor to gastritis. As awareness of the bacterial causes of gastritis increases, the demand for antibiotics in conjunction with other treatments is expected to soar.</p>

<p>Antacids (Dominant) vs. Histamine Blockers (Emerging)</p>

<p>Antacids have long been a dominant player in the Gastritis Treatment Market, providing quick symptomatic relief from indigestion and heartburn. Their wide availability and the ability to provide immediate comfort make them a staple choice for patients. In contrast, histamine blockers are emerging as an important treatment option, particularly as patients and doctors seek alternatives with fewer side effects. These blockers help to reduce stomach acid production but are less commonly used than antacids. The growing understanding of gastritis management and patient preference for continuous treatment over temporary relief may enhance the growth trajectory of histamine blockers.</p>

By Drug Distribution Channel: Retail Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

<p>In the Gastritis Treatment Market, the Retail Pharmacy segment commands the largest share, serving as the most accessible source for patients seeking medication. Retail pharmacies are integral to healthcare, providing a familiar and personal shopping experience, thus fostering customer loyalty. In contrast, the Online Pharmacy segment, although currently smaller in market share, is rapidly gaining traction among tech-savvy consumers looking for convenience and competitive pricing. The growth trends in the Drug Distribution Channel segment reflect changing patient behaviors and advancements in technology. The rising adoption of smartphones and online healthcare services is propelling the Online Pharmacy segment forward, making it the fastest-growing channel. Additionally, increasing awareness about gastritis and its treatment options fosters demand across all distribution channels, encouraging pharmacies to enhance their delivery and service offerings to meet patient needs.</p>

<p>Retail Pharmacy (Dominant) vs. Online Pharmacy (Emerging)</p>

<p>Retail Pharmacies remain dominant in the Gastritis Treatment Market, providing widespread access to medications and personalized customer service. They continue to build strong relationships with local healthcare providers, which enables them to seamlessly manage patient prescriptions and offer guidance on medication use. Meanwhile, Online Pharmacies represent an emerging channel, appealing particularly to younger consumers who prioritize convenience. This segment is characterized by user-friendly platforms offering home delivery, subscription services, and a broader variety of products. Both segments must adapt to regulatory challenges and consumer demands, but they collectively contribute to a diversified drug distribution landscape that caters to various customer preferences.</p>

By End-User: Hospitals & Clinics (Largest) vs. Others (Fastest-Growing)

<p>In the Gastritis Treatment Market, the distribution of market share among end-users is heavily skewed towards hospitals and clinics. This segment benefits from a well-established patient base relying on these facilities for diagnosis and treatment of gastritis. Hospitals not only provide immediate care but also have the infrastructure for advanced treatment protocols and long-term patient management. In contrast, the 'Others' segment, while having a smaller market share, is gaining traction as alternative treatment options and outpatient clinics become more accessible, catering to a growing demographic seeking cost-effective and time-efficient solutions.</p>

<p>End-User: Hospitals & Clinics (Dominant) vs. Others (Emerging)</p>

<p>Hospitals and clinics remain the dominant end-user segment in the Gastritis Treatment Market, providing comprehensive care through specialized gastroenterology departments. These establishments are equipped with skilled professionals and state-of-the-art technology, ensuring effective diagnosis and treatment methodologies that cater to varying severity levels of gastritis. On the other hand, alternative treatment avenues and outpatient facilities, represented in the 'Others' segment, are emerging as viable options. This shift is driven by a rising demand for minimalistic treatment and preventative care, as well as increasing awareness of gastritis management. These diverse treatment choices attract a wider range of patients, indicating a growing trend toward personalized and less invasive treatment approaches.</p>

Get more detailed insights about Gastritis Treatment Market Research Report – Forecast to 2035

Regional Insights

North America : Healthcare Innovation Leader

North America is the largest market for gastritis treatment, holding approximately 45% of the global share. The region benefits from advanced healthcare infrastructure, high prevalence of gastritis, and increasing awareness about gastrointestinal health. Regulatory support from agencies like the FDA further drives market growth, facilitating the approval of new therapies and treatments. Demand for innovative medications and personalized treatment options is on the rise, contributing to a robust market environment. The United States and Canada are the leading countries in this region, with major pharmaceutical companies like Pfizer, Bristol-Myers Squibb, and AbbVie actively involved in gastritis treatment development. The competitive landscape is characterized by a mix of established players and emerging biotech firms, focusing on research and development to introduce novel therapies. The presence of a well-established healthcare system and a growing patient population seeking effective treatments further enhances market dynamics.

Europe : Diverse Market Dynamics

Europe is the second-largest market for gastritis treatment, accounting for approximately 30% of the global market share. The region's growth is driven by increasing healthcare expenditure, a rising geriatric population, and a growing prevalence of gastritis-related disorders. Regulatory bodies like the European Medicines Agency (EMA) play a crucial role in ensuring the safety and efficacy of new treatments, which encourages innovation and market entry for new drugs. Leading countries in Europe include Germany, France, and the United Kingdom, where major pharmaceutical companies such as Novartis and GlaxoSmithKline are actively engaged in gastritis treatment. The competitive landscape is marked by collaborations between pharmaceutical firms and research institutions, focusing on developing advanced therapies. The presence of a diverse patient population and varying healthcare policies across countries adds complexity to market strategies, making it essential for companies to adapt to local regulations and patient needs.

Asia-Pacific : Emerging Market Potential

Asia-Pacific is witnessing significant growth in the gastritis treatment market, holding approximately 20% of the global share. The region's rapid urbanization, changing dietary habits, and increasing stress levels contribute to a higher prevalence of gastritis. Additionally, government initiatives aimed at improving healthcare access and affordability are expected to drive market expansion. Regulatory frameworks are evolving to support the introduction of new therapies, enhancing treatment options for patients. Key countries in this region include Japan, China, and India, where major players like Takeda Pharmaceutical and Sanofi are focusing on expanding their product portfolios. The competitive landscape is characterized by a mix of multinational corporations and local firms, each striving to capture market share through innovative solutions. The growing awareness of gastrointestinal health among the population is further propelling demand for effective gastritis treatments, making this region a focal point for future investments.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the gastritis treatment market, holding about 5% of the global share. The growth is primarily driven by increasing healthcare investments, rising awareness of gastrointestinal diseases, and government initiatives aimed at improving healthcare infrastructure. The region's diverse demographics and varying healthcare policies present both challenges and opportunities for market players. Regulatory bodies are working to streamline processes for drug approvals, which is expected to enhance market access for new treatments. Leading countries in this region include South Africa and the UAE, where local and international pharmaceutical companies are beginning to establish a presence. The competitive landscape is still developing, with a focus on building partnerships and collaborations to enhance distribution networks. As healthcare access improves and awareness grows, the demand for effective gastritis treatments is anticipated to rise, making this region an attractive market for investment.

Key Companies in the Gastritis Treatment Market market include

Industry Developments

Future Outlook

Gastritis Treatment Market Future Outlook

<p>The Gastritis Treatment Market is projected to grow at a 13.45% CAGR from 2024 to 2035, driven by increasing prevalence of gastritis and advancements in treatment options.</p>

New opportunities lie in:

  • <p>Development of personalized medicine approaches for gastritis treatment.</p>
  • <p>Expansion of telehealth services for remote patient monitoring.</p>
  • <p>Investment in innovative drug delivery systems for enhanced efficacy.</p>

<p>By 2035, the Gastritis Treatment Market is expected to achieve substantial growth and innovation.</p>

Market Segmentation

Gastritis Treatment Market End-User Outlook

  • Hospital & Clinics
  • Others

Gastritis Treatment Market Diagnosis Outlook

  • Blood test
  • Endoscopy
  • X-ray of upper digestive system
  • Others

Gastritis Treatment Market Treatment type Outlook

  • Acid-blocking medicines
  • Antibiotics
  • Antacids
  • Histamine Blockers

Gastritis Treatment Market Drug Distribution Channel Outlook

  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy

Report Scope

MARKET SIZE 20240.14(USD Billion)
MARKET SIZE 20250.1588(USD Billion)
MARKET SIZE 20350.561(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)13.45% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesIntegration of personalized medicine and digital health solutions in the Gastritis Treatment Market.
Key Market DynamicsRising demand for innovative therapies drives competition and influences treatment protocols in the gastritis treatment market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation for the Gastritis Treatment Market in 2035?

The projected market valuation for the Gastritis Treatment Market in 2035 is expected to reach 0.561 USD Billion.

What was the market valuation for the Gastritis Treatment Market in 2024?

The overall market valuation for the Gastritis Treatment Market was 0.14 USD Billion in 2024.

What is the expected CAGR for the Gastritis Treatment Market from 2025 to 2035?

The expected CAGR for the Gastritis Treatment Market during the forecast period 2025 - 2035 is 13.45%.

Which companies are considered key players in the Gastritis Treatment Market?

Key players in the Gastritis Treatment Market include Pfizer, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Takeda Pharmaceutical, Sanofi, AbbVie, and Mylan.

What are the primary segments of the Gastritis Treatment Market?

The primary segments of the Gastritis Treatment Market include Diagnosis, Treatment Type, Drug Distribution Channel, and End-User.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
    2. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
      5. Forecasting Model
      6. Market Size Estimation
      7. Data Triangulation
      8. Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    2. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
      3. COVID-19 Impact Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. Healthcare, BY Diagnosis (USD Billion)
      1. Blood test
      2. Endoscopy
      3. X-ray of upper digestive system
      4. Others
    2. Healthcare, BY Treatment type (USD Billion)
      1. Acid-blocking medicines
      2. Antibiotics
      3. Antacids
      4. Histamine Blockers
    3. Healthcare, BY Drug Distribution Channel (USD Billion)
      1. Retail Pharmacy
      2. Online Pharmacy
      3. Hospital Pharmacy
    4. Healthcare, BY End-User (USD Billion)
      1. Hospital & Clinics
      2. Others
    5. Healthcare, BY Region (USD Billion)
      1. North America
      2. Europe
      3. APAC
      4. South America
      5. MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Healthcare
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Healthcare
      7. Key developments and growth strategies
      8. Major Players Financial Matrix
    2. Company Profiles
      1. Pfizer (US)
      2. Novartis (CH)
      3. Bristol-Myers Squibb (US)
      4. GlaxoSmithKline (GB)
      5. AstraZeneca (GB)
      6. Takeda Pharmaceutical (JP)
      7. Sanofi (FR)
      8. AbbVie (US)
      9. Mylan (US)
    3. Appendix
      1. References
      2. Related Reports
  6. LIST OF FIGURES
    1. MARKET SYNOPSIS
    2. NORTH AMERICA MARKET ANALYSIS
    3. US MARKET ANALYSIS BY DIAGNOSIS
    4. US MARKET ANALYSIS BY TREATMENT TYPE
    5. US MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    6. US MARKET ANALYSIS BY END-USER
    7. CANADA MARKET ANALYSIS BY DIAGNOSIS
    8. CANADA MARKET ANALYSIS BY TREATMENT TYPE
    9. CANADA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    10. CANADA MARKET ANALYSIS BY END-USER
    11. EUROPE MARKET ANALYSIS
    12. GERMANY MARKET ANALYSIS BY DIAGNOSIS
    13. GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    14. GERMANY MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    15. GERMANY MARKET ANALYSIS BY END-USER
    16. UK MARKET ANALYSIS BY DIAGNOSIS
    17. UK MARKET ANALYSIS BY TREATMENT TYPE
    18. UK MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    19. UK MARKET ANALYSIS BY END-USER
    20. FRANCE MARKET ANALYSIS BY DIAGNOSIS
    21. FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    22. FRANCE MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    23. FRANCE MARKET ANALYSIS BY END-USER
    24. RUSSIA MARKET ANALYSIS BY DIAGNOSIS
    25. RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    26. RUSSIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    27. RUSSIA MARKET ANALYSIS BY END-USER
    28. ITALY MARKET ANALYSIS BY DIAGNOSIS
    29. ITALY MARKET ANALYSIS BY TREATMENT TYPE
    30. ITALY MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    31. ITALY MARKET ANALYSIS BY END-USER
    32. SPAIN MARKET ANALYSIS BY DIAGNOSIS
    33. SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    34. SPAIN MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    35. SPAIN MARKET ANALYSIS BY END-USER
    36. REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
    37. REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    38. REST OF EUROPE MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    39. REST OF EUROPE MARKET ANALYSIS BY END-USER
    40. APAC MARKET ANALYSIS
    41. CHINA MARKET ANALYSIS BY DIAGNOSIS
    42. CHINA MARKET ANALYSIS BY TREATMENT TYPE
    43. CHINA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    44. CHINA MARKET ANALYSIS BY END-USER
    45. INDIA MARKET ANALYSIS BY DIAGNOSIS
    46. INDIA MARKET ANALYSIS BY TREATMENT TYPE
    47. INDIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    48. INDIA MARKET ANALYSIS BY END-USER
    49. JAPAN MARKET ANALYSIS BY DIAGNOSIS
    50. JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    51. JAPAN MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    52. JAPAN MARKET ANALYSIS BY END-USER
    53. SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
    54. SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    55. SOUTH KOREA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    56. SOUTH KOREA MARKET ANALYSIS BY END-USER
    57. MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
    58. MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    59. MALAYSIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    60. MALAYSIA MARKET ANALYSIS BY END-USER
    61. THAILAND MARKET ANALYSIS BY DIAGNOSIS
    62. THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    63. THAILAND MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    64. THAILAND MARKET ANALYSIS BY END-USER
    65. INDONESIA MARKET ANALYSIS BY DIAGNOSIS
    66. INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    67. INDONESIA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    68. INDONESIA MARKET ANALYSIS BY END-USER
    69. REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
    70. REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    71. REST OF APAC MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    72. REST OF APAC MARKET ANALYSIS BY END-USER
    73. SOUTH AMERICA MARKET ANALYSIS
    74. BRAZIL MARKET ANALYSIS BY DIAGNOSIS
    75. BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    76. BRAZIL MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    77. BRAZIL MARKET ANALYSIS BY END-USER
    78. MEXICO MARKET ANALYSIS BY DIAGNOSIS
    79. MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    80. MEXICO MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    81. MEXICO MARKET ANALYSIS BY END-USER
    82. ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
    83. ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    84. ARGENTINA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    85. ARGENTINA MARKET ANALYSIS BY END-USER
    86. REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
    87. REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    88. REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    89. REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
    90. MEA MARKET ANALYSIS
    91. GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
    92. GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    93. GCC COUNTRIES MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    94. GCC COUNTRIES MARKET ANALYSIS BY END-USER
    95. SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
    96. SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    97. SOUTH AFRICA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    98. SOUTH AFRICA MARKET ANALYSIS BY END-USER
    99. REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
    100. REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    101. REST OF MEA MARKET ANALYSIS BY DRUG DISTRIBUTION CHANNEL
    102. REST OF MEA MARKET ANALYSIS BY END-USER
    103. KEY BUYING CRITERIA OF HEALTHCARE
    104. RESEARCH PROCESS OF MRFR
    105. DRO ANALYSIS OF HEALTHCARE
    106. DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. SUPPLY / VALUE CHAIN: HEALTHCARE
    109. HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
    110. HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
    111. HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    112. HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    113. HEALTHCARE, BY DRUG DISTRIBUTION CHANNEL, 2024 (% SHARE)
    114. HEALTHCARE, BY DRUG DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    115. HEALTHCARE, BY END-USER, 2024 (% SHARE)
    116. HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
    117. BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. LIST OF ASSUMPTIONS
    2. North America MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    3. US MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    4. Canada MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    5. Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    6. Germany MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    7. UK MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    8. France MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    9. Russia MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    10. Italy MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    11. Spain MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    12. Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    13. APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    14. China MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    15. India MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    16. Japan MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    17. South Korea MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    18. Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    19. Thailand MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    20. Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    21. Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    22. South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    23. Brazil MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    24. Mexico MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    25. Argentina MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    26. Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    27. MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    28. GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    29. South Africa MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    30. Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. BY DRUG DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. BY END-USER, 2025-2035 (USD Billion)
    31. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    32. ACQUISITION/PARTNERSHIP

Gastritis Treatment Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions